Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2?3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
This report contains market size and forecasts of Drugs for Herpes Labialis (Oral Herpes) in Global, including the following market information:
Global Drugs for Herpes Labialis (Oral Herpes) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Drugs for Herpes Labialis (Oral Herpes) market was valued at 2529.2 million in 2021 and is projected to reach US$ 3485.7 million by 2028, at a CAGR of 4.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Aciclovir Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Drugs for Herpes Labialis (Oral Herpes) include GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon and Luoxin, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs for Herpes Labialis (Oral Herpes) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Herpes Labialis (Oral Herpes) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Drugs for Herpes Labialis (Oral Herpes) Market Segment Percentages, by Type, 2021 (%)
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Global Drugs for Herpes Labialis (Oral Herpes) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Drugs for Herpes Labialis (Oral Herpes) Market Segment Percentages, by Application, 2021 (%)
External Use
Oral
Injection
Global Drugs for Herpes Labialis (Oral Herpes) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Drugs for Herpes Labialis (Oral Herpes) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Herpes Labialis (Oral Herpes) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Drugs for Herpes Labialis (Oral Herpes) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher

LEAVE A REPLY

Please enter your comment!
Please enter your name here